KALV KalVista Corp: רווח נקי למניה ב-12 החודשים האחרונים

The annual EPS TTM delta shows a metric value of -13.20, capturing profit dynamics. KalVista Pharmaceuticals (KALV) is implementing robotic manipulators and software to analyze the structure of plasma kallikrein. The use of AI and automated test benches accelerates the search for molecules to combat rare pathologies. Meanwhile, the company relies on contract organizations for conducting trials and the global distribution of drugs.
KALV (KalVista Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the rolling year net income per share dynamics, providing an objective assessment of business expansion rates via the percentage change in EPS. By analyzing the 12-month YoY EPS growth rate, an investor can discern the actual capitalization efficiency of KalVista Pharmaceuticals (KALV), which is currently exposed to risks of disrupted international clinical trials and patent disputes stemming from geopolitical instability.